Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurent Deferred Tax LiabilityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amdocs (DOX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Amdocs (DOX) over the last 17 years, with Q4 2025 value amounting to $325.0 million.

  • Amdocs' Cash & Equivalents rose 5198.73% to $325.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $325.0 million, marking a year-over-year increase of 5198.73%. This contributed to the annual value of $325.0 million for FY2025, which is 609.27% down from last year.
  • Per Amdocs' latest filing, its Cash & Equivalents stood at $325.0 million for Q4 2025, which was up 5198.73% from $325.0 million recorded in Q3 2025.
  • Amdocs' 5-year Cash & Equivalents high stood at $983.2 million for Q1 2021, and its period low was $213.8 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $519.1 million, with a median of $506.1 million in 2022.
  • Data for Amdocs' Cash & Equivalents shows a peak YoY increase of 10846.51% (in 2021) and a maximum YoY decrease of 4694.89% (in 2021) over the last 5 years.
  • Amdocs' Cash & Equivalents (Quarter) stood at $709.1 million in 2021, then plummeted by 30.59% to $492.2 million in 2022, then fell by 22.21% to $382.9 million in 2023, then tumbled by 44.15% to $213.8 million in 2024, then skyrocketed by 51.99% to $325.0 million in 2025.
  • Its Cash & Equivalents stands at $325.0 million for Q4 2025, versus $325.0 million for Q3 2025 and $346.1 million for Q2 2025.